Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a leading clinical-stage biopharmaceutical company specializing in the development of innovative therapies for immuno-inflammatory diseases. Founded by dermatologists, Aclaris leverages its extensive expertise in dermatologic treatments to address significant unmet needs in both medical and aesthetic dermatology.
Aclaris operates primarily through two segments: therapeutics and contract research. The therapeutics segment focuses on identifying and developing novel therapies to treat immuno-inflammatory diseases. Key drug candidates in this segment include Zunsemetinib, an oral MK2 inhibitor, ATI-2138, an ITJ inhibitor, and ATI-1777, a topical JAK 1/3 inhibitor. The contract research segment generates revenue by offering laboratory services, which constitute a significant portion of the company’s revenue.
Recent milestones for Aclaris include the progression of ATI-2138 into Phase 2a proof-of-concept trials for T cell-mediated autoimmune diseases and the completion of enrollment for the ATI-1777 Phase 2b trial in atopic dermatitis. Preliminary data from these trials have shown promising results, paving the way for further clinical development. Aclaris has also announced partnerships with institutions like Washington University to explore additional therapeutic applications for its drug candidates.
Financially, Aclaris maintains a robust liquidity position. As of the end of 2023, the company holds approximately $181.9 million in cash, cash equivalents, and marketable securities, ensuring the capability to fund operations through 2025. Revenue generation is primarily driven by contract research services and strategic licensing agreements, such as the recent deal with Sun Pharmaceutical Industries, Inc., which grants exclusive rights under certain patents for the use of deuruxolitinib in treating alopecia areata and androgenetic alopecia.
Aclaris Therapeutics (NASDAQ: ACRS) announced a non-exclusive patent license agreement with Eli Lilly for the use of baricitinib, a JAK inhibitor, to treat alopecia areata. The deal includes an upfront payment, regulatory and commercial milestones, and royalties. Jim Loerop, Chief Business Officer, emphasized the significance of the patent portfolio for commercialization, highlighting Aclaris' investment in its JAK inhibitor patents. Financial terms remain undisclosed, but the partnership positions Aclaris favorably within the competitive landscape of immuno-inflammatory disease treatments.
Aclaris Therapeutics (NASDAQ: ACRS) announced key updates on August 3, 2022, including the appointment of Douglas Manion, M.D., as President and COO. The company initiated Phase 2a study activities for Psoriatic Arthritis and reported a net loss of $20.5 million for Q2 2022, an increase from $18.2 million in Q2 2021. Total revenue for the quarter was $1.5 million, down from $1.8 million year-over-year. R&D expenses surged to $18.8 million, driven by advancements in clinical trials. Aclaris's cash position is robust, with $256 million available, ensuring operations through 2025.
Aclaris Therapeutics announces the appointment of Douglas Manion, M.D., as President and COO, effective August 1, 2022. Dr. Manion, who has over 25 years of experience in the pharmaceutical industry, will oversee day-to-day operations and help shape the company’s strategic direction alongside CEO Neal Walker. His previous roles include leadership positions at Arena Pharmaceuticals and Bristol-Myers Squibb. This leadership change aims to strengthen Aclaris' R&D capabilities and advance its pipeline of drug candidates for immuno-inflammatory diseases.
Aclaris Therapeutics, Inc. announces the appointment of Gail Cawkwell, MD, PhD, as its new Chief Medical Officer, effective June 27, 2022. Dr. Cawkwell brings over 20 years of experience in pharmaceutical development, most recently as Senior Vice President at Intercept Pharmaceuticals. Her expertise includes working in various disease areas and includes a strong clinical background. The company aims to leverage her leadership to advance its clinical pipeline, focusing on treatments for immuno-inflammatory diseases.
Aclaris Therapeutics, a clinical-stage biopharmaceutical firm focused on immuno-inflammatory diseases, announced that Dr. Neal Walker, President and CEO, will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2022, at 11:30 a.m. ET in New York. The session will also allow for 1x1 meetings on the same day. A live webcast of the chat will be available on Aclaris’ website and archived for 30 days. The company is known for its innovative drug candidates aimed at addressing unmet patient needs in this therapeutic area.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company, announced that Dr. Neal Walker, President and CEO, will present a company overview virtually at the H.C. Wainwright Global Investment Conference. The presentation will be accessible starting May 24, 2022, at 7:00 a.m. ET. Additionally, management will conduct 1x1 virtual meetings on May 23. This event marks a significant opportunity for investors and stakeholders to gain insights into Aclaris’ innovative drug candidates aimed at immuno-inflammatory diseases. The presentation will be archived on Aclaris’ website for 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) reported its first-quarter 2022 financial results, revealing a net loss of $18.8 million, a decrease from $28.8 million in Q1 2021. Total revenue was $1.5 million, down from $1.8 million year-over-year. R&D expenses surged to $14.3 million, primarily due to increased costs for drug development. Aclaris activated multiple clinical sites for its Phase 2b trial of ATI-1777 for atopic dermatitis and anticipates data in 2023. Following a recent capital raise of $73 million, the company expects its cash runway to extend through 2025.
Aclaris Therapeutics (NASDAQ: ACRS) announced participation in a virtual fireside chat at the LifeSci Partners Immunology & Inflammation Symposium on May 11, 2022, at 9:00 a.m. ET. President and CEO Dr. Neal Walker and Consultant Walter Smith will discuss the company’s initiatives in developing novel drug candidates for immuno-inflammatory diseases. The chat will be accessible via Aclaris’ website and archived for 30 days. Aclaris is focused on innovative treatments for patients with unmet medical needs in immuno-inflammatory diseases.
Aclaris Therapeutics (NASDAQ: ACRS) announced its 2021 financial results, reporting a net loss of $90.9 million compared to $51.0 million in 2020. Total revenue increased to $6.8 million from $6.5 million. The company highlighted positive data from Phase 2a trials of zunsemetinib for rheumatoid arthritis and ATI-1777 for atopic dermatitis. As of December 31, 2021, Aclaris had $225.7 million in cash, sufficient to fund operations through 2024. R&D expenses rose to $43.8 million, driven by ongoing clinical trials. Aclaris aims to progress multiple drug candidates in 2022.
Aclaris Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: ACRS), announced that Dr. Neal Walker, its President and CEO, will join a fireside chat at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on February 16, 2022, at 9:20 a.m. ET. Aclaris management will also be available for virtual one-on-one meetings that day. The fireside chat webcast can be accessed via the company's website and will be archived for 30 days. Aclaris focuses on developing novel treatments for immuno-inflammatory diseases, backed by a strong R&D pipeline.
FAQ
What is the current stock price of Aclaris Therapeutics (ACRS)?
What is the market cap of Aclaris Therapeutics (ACRS)?
What is Aclaris Therapeutics, Inc. focused on?
What are the key drug candidates Aclaris is developing?
What recent clinical trial milestones has Aclaris achieved?
How does Aclaris generate revenue?
What was the recent licensing agreement with Sun Pharmaceutical Industries about?
What is Aclaris' financial position as of the end of 2023?
What partnerships does Aclaris have for clinical development?
What is the significance of ATI-2138's recent trial results?
What is the focus of Aclaris' therapeutics segment?
What makes Aclaris unique in the biopharmaceutical industry?
